---
schema_version: "secwatch.filing_event.v1"
accession: "0001387131-23-006126"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T12:42:29.172132+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tonix Q1 net loss $33M, cash $72M; Phase 3 TNX-102 SL topline due Q4 2023

## Summary
- Net loss $33.0M ($0.52 per share) vs $26.4M ($1.61) in Q1 2022; cash $72.0M at Mar 31, 2023, down from $120.2M at Dec 31, 2022.
- R&D expenses $26.5M (up from $18.4M) due to advancing clinical programs; G&A decreased to $7.4M from $8.0M.
- Cash used in operations $32.9M vs $31.0M; share repurchase of 16.7M shares at $0.82 avg for $13.6M.
- Pipeline: TNX-102 SL Phase 3 RESILIENT topline expected Q4 2023; TNX-601 ER Phase 2 enrolling; TNX-1900 Phase 2 enrolling.
- Company reallocated resources to focus on late-stage CNS programs; delayed PTSD study in Kenya and reduced COVID-19 investment.

## SEC filing metadata
- accession: 0001387131-23-006126
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000138713123006126/0001387131-23-006126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000138713123006126/tnxp_8k-050823.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001387131-23-006126
- JSON: https://secwatch.observer/filing/0001387131-23-006126.json
- Plain text: https://secwatch.observer/filing/0001387131-23-006126.txt

## Key facts
- Earnings Releases
  Tonix Pharmaceuticals Holding Corp. reported financial results for first quarter ended March 31, 2023.
  - Period: first quarter ended March 31, 2023
  - Result: reported results
  source text: On May 8, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1430306/000138713123006126/0001387131-23-006126-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.